Generated by AI
Imunon Inc. is a clinical-stage biotechnology company focused on developing DNA-based immunotherapies and vaccines for difficult-to-treat diseases. The company’s current portfolio centers on proprietary non-viral DNA platforms designed to activate the body’s immune system at the site of disease, with applications in oncology and infectious diseases. Its lead program, IMNN-001, is being developed as a localized immunotherapy for advanced ovarian cancer, while its PlaCCine platform supports nucleic acid vaccine research for infectious disease targets. Imunon also advances additional preclinical and early-stage programs across solid tumors and viral indications. Headquartered in Lawrenceville, New Jersey, Imunon plays a specialized role in the biotechnology market by pursuing platform-based treatments that combine immunology, gene delivery, and cancer therapy research.
Website997 Lenox Drive
Lawrenceville, NJ, 08648
United States
The latest articles about IMNN.
Detailed price information for Arm Holdings Plc ADR (ARM-Q) from The Globe and Mail including charting and trades.
Summary of Nov 12's posts. Generated by AI.
Summary of Jul 30's posts. Generated by AI.
Summary of Jul 21's posts. Generated by AI.
Investors talking about IMNN also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.